Federal Register Notice: FDA has determined the regulatory review period for American Home Products’ Prevnar is 1,910 days for the extension of a patent which claims that human biological product. Prevnar is indicated for immunization of infants 2, 4, 6, and 12 to 15 months of age to prevent invasive pneumococcal disease. To view this notice, click here.
